Upstream Bio Adds Another $200M for Asthma, Allergy Pipeline

Upstream Bio has closed a $200m Series B funding round to enable the advancement of its investigational antibody UPB-101 for mid-stage studies in asthma and chronic rhinosinusitis with nasal polyps. The start-up will also undergo "translational, manufacturing and device development activities" to aid the launch of its Phase III development program. In addition, Thursday’s Series B raise will all..